Victory Square Technologies Portfolio Company Enters into Sales & Distribution Agreement for Safetest 15 Minute Covid-19 Rapid Test for North America with ProNorth Medical Corp.

• Victory Square Health has entered into a new sales & distribution agreement with ProNorth Medical Corporation to provide its Safetest 15 minute Covid-19 Rapid Testing kits in the United States of America and in Canada* following Health Canada approvals.
  

• ProNorth Medical currently has multi-million dollar PPE products sales and distribution contracts with government, hospitals, and the private sector across North America.
  

• North America has seen an additional 135,622 cases totaling 10,573,000 and 250,632 deaths from Covid-19 as of November 9, 2020 (source: Code 19 Alert)
  

• VSH Safetest Antibody Rapid Test products are critical because they identify if one has had or is currently infected with the Covid-19 virus. The end-user would know if previously infected with the virus, will have the antibodies present
  

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (“VS Health” or the “Company“) – a portfolio company of Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) — is pleased to announce that it has entered into a sales & distribution agreement with ProNorth Medical, a North American Sales and Distribution Company, to sell its Safetest 15 minute Covid-19 Rapid Testing kits in the United States of America and in Canada* following Health Canada approvals.

ProNorth Medical has been proudly servicing Medical, Veterinary, and Dental professionals across North America for the past 9 years. ProNorth Medical CEO Robert Horne has a 30 plus year record in the medical sales and distribution sector, having worked with Johnson & Johnson for over 25 years prior to launching ProNorth Medical Corporation in 2011. ProNorth Medical currently has multi-million dollar Canadian and USA tested PPE products sales and distribution contracts with government, hospitals, and the private sector. ProNorth Medical clients in Canada include Hamilton Health Sciences Centre, The Ottawa Hospital, Vitalite Health Network, Service New Brunswick and Horizon Health. In addition, ProNorth Medical will engage with strategic film industry partners in the United States to provide major film studios, production companies, talent and crew with Safetest Covid-19 Testing products for detecting the antibodies IgG and IgM against SARS-CoV-2.

Pro North Medical associate, film producer and actor Cody Hackman who has produced films for Netflix, Lionsgate, MGM and many other companies says, “Our industry is anxiously waiting to safely resume pre-pandemic production volumes. Productions are finally starting to ramp up again but are now taking more time and are more costly due to Covid19. The Safetest Covid-19 Rapid Test from Victory Square Health will enable our industry to open up more quickly, safely, efficiently, and effectively to reduce the extra costs and production delays occurring due to Covid.”

“I am very pleased to have partnered with Victory Square Health to quickly and efficiently distribute and sell its Safetest Covid-19 suite of testing products to our network in the USA and hopefully soon throughout Canada with health approvals,” said Robert Horne, CEO ProNorth Medical. “Our Company has already received inquiries and requests/demand for the VSH Safetest Covid-19 Rapid test from our extensive network in America.”

Felipe Peixoto, CEO of VSH said, “The global vaccination process is a positive step towards tackling the world pandemic crisis, however, that will take many months if not years to cover the global population. Our Antibody Rapid Test products are critical in the process because they identify if one has had or is currently infected with the Covid-19 virus. By simply taking a drop of blood, the end-user, if previously infected with the virus, will have the antibodies present and know that he/she is not urgently required to take a vaccination.”

The Safetest 15 minute Covid-19 Rapid Testing kit enables the user to receive results with 96.6% sensitivity in 15 minutes by a simple blood sample similar to that of a hand held diabetes reader that resembles a pregnancy test stick. This highly accurate test enables the participant to quickly detect if they have Covid-19 antibodies in 15 minutes.

The Safetest 15 Minute Covid-19 Rapid Test has been granted permission by the Food & Drug Administration (FDA) in the United States to commence marketing, sales and distribution under the emergency use authorization (EUA). The Safetest 15 Minute Covid-19 Rapid Test has been approved for sale and distribution in the European Union and submitted for review and approval in Canada.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.

Disclaimer:
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Go to: VictorySquare.com and sign up for VST’s official newsletter at www.VictorySquare.com/newsletter

On behalf of the board,

Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios
Email: alexandros@victorysquare.com
Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups
VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors
VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they’re unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.